Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

nowledge of our business, have broad experience and are committed to serving the best interests of all our shareholders. They have helped to build Amylin's leading portfolio of products and drug candidates and are a critical reason why the company is well positioned for significant future growth.

It is important to stress our conviction that the Icahn and Eastbourne objective to replace up to ten members of the Board would not serve the interests of the shareholders as a whole. Neither Icahn nor Eastbourne has articulated any business strategy for the company. We believe the ten nominees they have stated they intend to put forward collectively lack the experience and expertise necessary to maximize value for our shareholders and the commercialization expertise that many of our shareholders desire.

Recent Activities by Certain Shareholders

Icahn and Eastbourne had each stated their intention to nominate a slate of five directors for election to our Board at our upcoming annual meeting. On Monday, March 30, 2009, we learned that the Securities and Exchange Commission (the "SEC") granted Icahn and Eastbourne "no action" relief that would allow them to include each other's nominees on their proxy cards - thus, up to a total of ten nominees between them out of the twelve seats up for election.

While seeking the SEC's approval to do this, Icahn and Eastbourne had also raised concerns about provisions in our debt agreements. Eastbourne has publicly supported a lawsuit brought on March 27, 2009 by the San Antonio Fire & Police Pension Fund challenging debt acceleration provisions in two of our debt agreements, and Icahn is participating in that lawsuit.

Change-in-control provisions of the type found in our agreements are designed solely to protect the interests of creditors and are common in the marketplace. For example, of the 26 comparable biotechnology companies with publicly
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for cancer, announced today ... Officer of the Company, will be making an Industry ... in Chicago on Saturday, May ... the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... of the Company,s Series A and Series A-1 ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March 31, ... Series A Preferred Stock and Series A-1 Preferred ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... Researchers at the National Institute of Standards and Technology ... complex viscosity measurementscritical data for a wide variety of ... sizes as small as a few nanoliters. Currently a ... valuable tool for biotechnologists studying minute quantities of complex ...
... MATK ) today announced its financial results for ... quarter were $117.2 million, up 51% from $77.8 million in ... $11.9 million, or $0.35 per diluted share, for the third ... $8.9 million, or $0.27 per diluted share, for the third ...
... , the semiconductor sequencing company, today announced that it ... Pioneers for 2011. The winning companies were chosen from a field ... expected to have on the future of business and society. ... and CEO, was selected to represent the company at Davos in ...
Cached Biology Technology:Micro rheometer is latest Lab On a Chip device 2Martek Announces Third Quarter FY 2010 Financial Results 2Martek Announces Third Quarter FY 2010 Financial Results 3Martek Announces Third Quarter FY 2010 Financial Results 4Martek Announces Third Quarter FY 2010 Financial Results 5Martek Announces Third Quarter FY 2010 Financial Results 6Martek Announces Third Quarter FY 2010 Financial Results 7Martek Announces Third Quarter FY 2010 Financial Results 8Martek Announces Third Quarter FY 2010 Financial Results 9Martek Announces Third Quarter FY 2010 Financial Results 10Martek Announces Third Quarter FY 2010 Financial Results 11Martek Announces Third Quarter FY 2010 Financial Results 12Martek Announces Third Quarter FY 2010 Financial Results 13Martek Announces Third Quarter FY 2010 Financial Results 14Ion Torrent Selected as World Economic Forum Technology Pioneer 2Ion Torrent Selected as World Economic Forum Technology Pioneer 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... study shows that the concentration of polycyclic aromatic,hydrocarbons (PAHs) ... much as,60 fold, with the highest levels in moist ... were in snus. Higher levels can be explained by ... source of the trace amounts of PAHs in snus ...
... Qi-Long Ying and a team of researchers have long been ... ways to encourage embryonic stem cells (ESCs) and epiblast stem ... stem cells. In a pair of studies published in ... EMBO Journal in August, Ying and his team revealed ...
... and physicians at The Johns Hopkins University will ... advance silicon applications in health care, beginning with ... broad range of clinical tests to be performed ... combine the Johns Hopkins clinical and research expertise ...
Cached Biology News:Polycyclic aromatic hydrocarbons in smokeless tobacco products 2USC researcher reveals how to better master stem cells' fate 2Johns Hopkins And Belgian research center to expand health care applications for silicon nanotech 2
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Request Info...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: